Wed, Jan 28, 2015, 3:47 PM EST - U.S. Markets close in 13 mins.


% | $
Quotes you view appear here for quick access.

Sunesis Pharmaceuticals, Inc. Message Board

  • fuchujoe fuchujoe Aug 2, 2013 10:51 AM Flag


    Sorry I haven't answered you but I'm having trouble accessing that thread . I can't make out your messages.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You had mentioned Cambridge not being a part of the valor study.. From the info on the CDC website there are only two vosaroxin studies, the main one having 124 sites including Cambridge and the other one dealing with MDS and having one site in Texas. Where did you get your info from re: Cambridge?



      • 1 Reply to robchadwick
      • Hey Rob. I apologize if my wording was a bit misleading. I meant to say that the Cardiff LI-1 Pick a winner study and Valor are different trials. There are many sources, but probably the most understandable is the recent Sunesis Corporate Presentation June 2013. It lists the trials as seperate, biggest differences being - Relapsed/Refractory vs. Frontline ~ Age 18 and up vs. 60 and up ~ over 675 patients vs. 53(monotherpy). The LI-1 is one trial, like you said, but it has TWO seperate trial arms, one being the monotherapy vosaroxin arm, which was discontinued causing the pps drop , and a combination vosaroxin and cytarbine arm (like Valor but with differences mentioned above), which will be reported on later this year. I hope this answered your question. GLTU

2.32-0.05(-2.11%)3:47 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.